⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LSTA News
Lisata Therapeutics, Inc. Common Stock
Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’
globenewswire.com
LSTA
Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
globenewswire.com
LSTA
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
globenewswire.com
LSTA
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
globenewswire.com
LSTA
Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial
globenewswire.com
LSTA